Eldred Rock Boosts Novartis Stake 12.2% to $11.64M as Q3 Sales Rise 8.5%
Eldred Rock Partners increased its Novartis holdings by 12.2% to 90,753 shares, valued at $11.64 million, making it the fund’s 18th largest position. In the third quarter Novartis reported revenue of $14.36 billion, up 8.5% year-over-year, and EPS of $2.25, missing estimates by $0.01.
1. Eldred Rock Partners Boosts Novartis Stake
In its latest SEC filing, Eldred Rock Partners LLC disclosed a 12.2% increase in its position in Novartis AG during the third quarter, acquiring an additional 9,871 shares to bring its total to 90,753. This holding, valued at approximately $11.64 million, represents 2.9% of the firm’s investment portfolio and ranks as its 18th largest position. The move underscores Eldred Rock’s continued conviction in Novartis’s long-term growth prospects within the pharmaceutical sector.
2. Other Institutional Activity in Novartis
Several smaller investment managers initiated or expanded positions in Novartis during the second quarter. GFG Capital LLC added a new stake valued near $26,000, while Legacy Investment Solutions LLC and Barrett & Company Inc. each established positions worth roughly $30,000 and $31,000, respectively. MCF Advisors LLC increased its holding by 66.0% to 264 shares, and Highline Wealth Partners LLC grew its stake by 82.4% to 290 shares. Collectively, these moves illustrate growing interest from boutique investors, though institutional ownership of Novartis remains at about 13.1%.
3. Third-Quarter Financial Performance
Novartis reported third-quarter earnings per share of $2.25, narrowly missing the consensus estimate of $2.26. Revenue reached $14.36 billion, surpassing expectations of $13.70 billion and marking an 8.5% year-over-year increase. The company delivered a return on equity of 41.2% and maintained a net margin of 26.5%. Analysts now project full-year earnings of $8.45 per share, reflecting confidence in ongoing revenue growth across key franchises such as oncology, immunology and advanced therapies.
4. Analyst Ratings and Consensus
Following the latest earnings release, research firms have largely maintained a cautious stance. Of the analysts covering Novartis, one has issued a Strong Buy recommendation, five carry Buy ratings, six cite Hold and three assign Sell. The consensus view remains a Hold rating, indicating a balanced risk-return profile. Recent rating actions include Morgan Stanley’s reaffirmation of an Overweight rating and CFRA’s Hold assessment, reflecting divergent views on valuation and pipeline catalysts ahead.